JP4638608B2 - 癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１） - Google Patents

癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１） Download PDF

Info

Publication number
JP4638608B2
JP4638608B2 JP2000611082A JP2000611082A JP4638608B2 JP 4638608 B2 JP4638608 B2 JP 4638608B2 JP 2000611082 A JP2000611082 A JP 2000611082A JP 2000611082 A JP2000611082 A JP 2000611082A JP 4638608 B2 JP4638608 B2 JP 4638608B2
Authority
JP
Japan
Prior art keywords
timp
cancer
parameter
plasma
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000611082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002541481A5 (fr
JP2002541481A (ja
Inventor
マッズ ホルテン−アンダーソン
ロス ダブリュ． ステファンス
ハンス ヨルゲン ニールセン
イブ ジャルレ クリスチャンセン
ニルス ブリュンナー
Original Assignee
リグズホスピタレット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リグズホスピタレット filed Critical リグズホスピタレット
Publication of JP2002541481A publication Critical patent/JP2002541481A/ja
Publication of JP2002541481A5 publication Critical patent/JP2002541481A5/ja
Application granted granted Critical
Publication of JP4638608B2 publication Critical patent/JP4638608B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000611082A 1999-04-09 2000-04-10 癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１） Expired - Fee Related JP4638608B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK199900476 1999-04-09
DKPA199900476 1999-04-09
PCT/DK2000/000170 WO2000062070A2 (fr) 1999-04-09 2000-04-10 Inhibiteur tissulaire de metalloproteinases matricielles type-1 (timp-1) comme marqueur de cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010152840A Division JP2010266455A (ja) 1999-04-09 2010-07-05 癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１）

Publications (3)

Publication Number Publication Date
JP2002541481A JP2002541481A (ja) 2002-12-03
JP2002541481A5 JP2002541481A5 (fr) 2007-05-24
JP4638608B2 true JP4638608B2 (ja) 2011-02-23

Family

ID=8093987

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000611082A Expired - Fee Related JP4638608B2 (ja) 1999-04-09 2000-04-10 癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１）
JP2010152840A Ceased JP2010266455A (ja) 1999-04-09 2010-07-05 癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１）

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010152840A Ceased JP2010266455A (ja) 1999-04-09 2010-07-05 癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１）

Country Status (11)

Country Link
US (6) US7108983B1 (fr)
EP (2) EP1619206A3 (fr)
JP (2) JP4638608B2 (fr)
AT (1) ATE298890T1 (fr)
AU (1) AU771309B2 (fr)
CA (2) CA2652131A1 (fr)
DE (1) DE60021068T2 (fr)
ES (1) ES2244417T3 (fr)
NO (1) NO329725B1 (fr)
NZ (1) NZ515311A (fr)
WO (1) WO2000062070A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298890T1 (de) 1999-04-09 2005-07-15 Rigshospitalet Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
US20060154245A1 (en) * 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
US7091323B2 (en) 2001-04-24 2006-08-15 Bayer Corporation Human TIMP-1 antibodies
WO2003087830A2 (fr) * 2002-04-08 2003-10-23 Rigshospitalet Inhibiteur tissulaire des metalloproteinases matricielles de type-1 (timp-1) en tant que marqueur postoperatoire de maladie residuelle minime ou de maladie recurrente chez des patients presentant des antecedents de cancer
AU2003269837B9 (en) * 2002-09-26 2009-07-30 Hvidovre Hospital A method for detecting, screening and/or monitoring a cancer in an individual
EP1613966A2 (fr) * 2003-04-08 2006-01-11 Colotech A/S Procede de detection d'un cancer colorectal dans des echantillons humains
WO2005094863A1 (fr) * 2004-03-30 2005-10-13 Den Kgl.Veterinær-Og Landbohøjskole Ameliorations dans le traitement du cancer et prediction efficace de traitement du cancer par le blocage et la detection d'inhibiteurs de la protease
US20100196889A1 (en) * 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
EP2126562B1 (fr) * 2007-02-23 2014-12-31 Physicians Choice Laboratory Services, LLC Procede diagnostique destine a une intervention clinique
CN101680898A (zh) * 2007-05-10 2010-03-24 霍夫曼-拉罗奇有限公司 Timp-1作为结肠直肠癌标志的用途
FR2919060B1 (fr) 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919061B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
US9726670B2 (en) * 2007-07-19 2017-08-08 Biomerieux Method for the assay of liver fatty acid binding protein, ACE and CA 19-9 for the in vitro diagnosis of colorectal cancer
WO2009091581A2 (fr) * 2008-01-18 2009-07-23 Vatrix Medical, Inc. Biomarqueurs de diagnostic pour anévrisme vasculaire
CN101971027A (zh) 2008-01-23 2011-02-09 海莱乌医院 作为非特异疾病的通用标记的ykl-40
CA2727559A1 (fr) * 2008-06-11 2009-12-17 Nils Aage Brunner Choix de patients souffrant d'un cancer colorectal pour l'administration d'un traitement anticancereux systemique neo-adjuvant et adjuvant
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
NZ592241A (en) 2008-09-15 2012-11-30 Herlev Hospital Ykl-40 as a marker for gastrointestinal cancers
DE102009015784A1 (de) * 2009-03-31 2010-12-02 Siemens Aktiengesellschaft In-vitro-Verfahren zur Diagnostik von Tumorerkrankungen
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
JP6182308B2 (ja) * 2012-11-13 2017-08-16 株式会社エイアンドティー 前立腺癌の鑑別診断に用いるための泳動波形データの処理方法
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
CN111971559A (zh) * 2018-04-13 2020-11-20 生态学有限公司 监测对治疗的响应的方法
WO2021039616A1 (fr) * 2019-08-23 2021-03-04 大日本住友製薬株式会社 Polythérapie et biomarqueur indiquant l'efficacité de celle-ci

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US111359A (en) * 1871-01-31 Improvement in sewing-machines
US234776A (en) * 1880-11-23 Belt-coupling
US62070A (en) * 1867-02-12 And jeremiah kimbrough
US2086085A (en) * 1935-05-14 1937-07-06 Handley Page Ltd Aircraft control gear
US3087830A (en) * 1958-12-17 1963-04-30 Schuller Werner Hugo Wilhelm Method and apparatus for producing a dry mat sheet
US3006671A (en) * 1959-08-03 1961-10-31 Gen Precision Inc Internal staking
US6271352B1 (en) 1985-07-12 2001-08-07 Fonden Til Fremme Af Eksperimentel Cancerforskning PAI-1 determination and use thereof
US5356817A (en) * 1988-06-09 1994-10-18 Yale University Methods for detecting the onset, progression and regression of gynecologic cancers
FR2657700A1 (fr) 1990-01-26 1991-08-02 Thomson Csf Modulateur electrooptique spatial et applications.
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
JPH0813654A (ja) 1994-07-01 1996-01-16 Sekisui House Ltd 断熱壁下地パネルの施工構造
US5569458A (en) * 1994-09-14 1996-10-29 Greenberg; Mike Nutritional formula
JPH08136548A (ja) * 1994-11-11 1996-05-31 Morinaga & Co Ltd 泌尿器癌の診断法
JP2864219B2 (ja) * 1995-02-20 1999-03-03 富士薬品工業株式会社 遊離の活性型マトリックスメタロプロテアーゼ類の分別定量法
US5643752A (en) 1996-01-18 1997-07-01 Incyte Pharmaceuticals, Inc. Tissue inhibitor of metalloproteinases
GB9607287D0 (en) * 1996-04-09 1996-06-12 British Biotech Pharm Diagnosis method
JPH10287700A (ja) * 1997-04-10 1998-10-27 Fuji Yakuhin Kogyo Kk 活性型マトリライシン（ｍｍｐ−７）に対する抗体及びそれを用いた免疫学的測定法
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
CN1236102A (zh) 1998-05-20 1999-11-24 徐国光 唾液癌胚抗原快速检测试剂
WO2000020860A1 (fr) 1998-10-08 2000-04-13 Calbiochem Novabiochem Corporation Methode diagnostique de detection de metalloprotease matricielle-9 et utilisation de ladite methode
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
US20060154245A1 (en) 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
ATE298890T1 (de) 1999-04-09 2005-07-15 Rigshospitalet Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
US6630163B1 (en) * 1999-04-22 2003-10-07 Howard Murad Method of treating dermatological disorders with fruit extracts
WO2001011359A2 (fr) 1999-08-06 2001-02-15 Imi International Medical Innovations Inc. Mesure spectrophotometrique dans des dosages biochimiques et immunologiques chromatiques
US7306643B2 (en) * 2000-01-10 2007-12-11 Sulzer Chemtech Ag Method for introducing additives to liquid metal, ceramic/metallic powder
AU2002211697B2 (en) 2000-10-13 2005-12-15 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
AU2002216847A1 (en) 2000-10-26 2002-05-06 K.U. Leuven Research And Development Epitopes of pai-1
AU2085502A (en) 2000-11-30 2002-06-11 Molecular Skincare Ltd Diagnosis and treatment of disease
US7091323B2 (en) 2001-04-24 2006-08-15 Bayer Corporation Human TIMP-1 antibodies
US6815181B2 (en) 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
AU2002365066A1 (en) 2001-07-18 2003-07-09 American Red Cross Mutant proteinase inhibitors and uses thereof
KR100475642B1 (ko) 2001-12-29 2005-03-10 한국생명공학연구원 암 발생 및 전이에 관여하는 단백질의 당쇄 변화를측정하여 암을 진단하는 방법 및 이를 이용한 진단킷트
WO2003087830A2 (fr) 2002-04-08 2003-10-23 Rigshospitalet Inhibiteur tissulaire des metalloproteinases matricielles de type-1 (timp-1) en tant que marqueur postoperatoire de maladie residuelle minime ou de maladie recurrente chez des patients presentant des antecedents de cancer
EP1382969A1 (fr) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnostic et traitement de l'invasion des cellules cancéreuses
AU2003269837B9 (en) 2002-09-26 2009-07-30 Hvidovre Hospital A method for detecting, screening and/or monitoring a cancer in an individual
US20040157278A1 (en) 2002-12-13 2004-08-12 Bayer Corporation Detection methods using TIMP 1
ES2369667T3 (es) 2003-07-17 2011-12-02 Pacific Edge Limited Marcadores para la detección del cáncer gástrico.
WO2005094863A1 (fr) * 2004-03-30 2005-10-13 Den Kgl.Veterinær-Og Landbohøjskole Ameliorations dans le traitement du cancer et prediction efficace de traitement du cancer par le blocage et la detection d'inhibiteurs de la protease

Also Published As

Publication number Publication date
EP1171771B1 (fr) 2005-06-29
AU771309B2 (en) 2004-03-18
CA2366682C (fr) 2009-06-23
ES2244417T3 (es) 2005-12-16
DE60021068T2 (de) 2006-05-18
ATE298890T1 (de) 2005-07-15
EP1619206A2 (fr) 2006-01-25
AU3655600A (en) 2000-11-14
EP1619206A3 (fr) 2006-02-15
US20080261246A1 (en) 2008-10-23
WO2000062070A3 (fr) 2001-01-25
US20090035794A1 (en) 2009-02-05
CA2652131A1 (fr) 2000-10-19
WO2000062070A2 (fr) 2000-10-19
JP2010266455A (ja) 2010-11-25
NO20014869D0 (no) 2001-10-05
US20110060529A1 (en) 2011-03-10
DE60021068D1 (de) 2005-08-04
NO20014869L (no) 2001-12-04
CA2366682A1 (fr) 2000-10-19
US20070020707A1 (en) 2007-01-25
US7108983B1 (en) 2006-09-19
US20110294148A1 (en) 2011-12-01
EP1171771A2 (fr) 2002-01-16
JP2002541481A (ja) 2002-12-03
US7807379B2 (en) 2010-10-05
NO329725B1 (no) 2010-12-06
NZ515311A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
JP4638608B2 (ja) 癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１）
Holten-Andersen et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer
Zucker et al. Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer
Jung et al. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase‐1 and the complex of metalloproteinase‐1/tissue inhibitor in plasma of patients with prostate cancer
Jiang et al. Plasma Inter‐Alpha‐Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer
Groblewska et al. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients
US7374886B2 (en) Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
Niewiarowska et al. Diagnostic significance of TIMP-1 level in serum and its immunohistochemical expression in colorectal cancer patients
EP1561113B1 (fr) Methode de detection et/ou depistage de surveillance d'un cancer colorectal chez un individu
Monier et al. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas
KR100395254B1 (ko) 종양 발생 예측 키트
US20060154245A1 (en) Method for detecting, screening and/or montoring a cancer in individual
WO2003087830A2 (fr) Inhibiteur tissulaire des metalloproteinases matricielles de type-1 (timp-1) en tant que marqueur postoperatoire de maladie residuelle minime ou de maladie recurrente chez des patients presentant des antecedents de cancer
CN112129954B (zh) Mmp7、ctse或lamc2蛋白在制备肝内胆管细胞癌诊断试剂中的应用
Tas et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma
Swellam et al. Clinical implications of proteolytic activity imbalance in breast cancer diagnosis
US20110165577A1 (en) Selection of colorectal cancer patients for neo-adjuvant and adjuvent systemic anti-cancer treatment
US20220390453A1 (en) Ovarian cancer biomarker and methods of using same
Di Carlo et al. Gelatinolytic activities (matrix metalloproteinase-2 and-9) and soluble extracellular domain of Her-2/neu in pleural effusions
CA3163199A1 (fr) Biomarqueur du cancer des ovaires et ses procedes d~utilisation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070320

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090306

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101004

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101126

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131203

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees